Patients with 
NAFLD, cirrhosis, Cirrhosis, Liver Stiffness
TYPE 2 DIABETES, CIRRHOSIS, CIRRHOSIS, INSULIN RESISTANCE
General characteristics of study participants are presented in Table Clinical, anthropometric and biochemical data at baseline in healthy, NAFLD and cirrhosis.
Abbreviations: A1c, Hemoglobin A1C; ALT, Alanine Transferase; AST, Aspartate Transferase; BMI; Body Mass Index; CAP, Controlled Attenuation Parameter; FGF‐21, Fibroblast‐Growth‐Factor 21; FIB‐4, Fibrosis‐4; HDL, High‐Density Lipoprotein; HOMA‐IR, Homeostatic Model Assessment for Insulin Resistance; HVPG, Hepatic Venous Pressure Gradient; LSM, Liver Stiffness Measurement; NAS Score, NAFLD Activity Score; T2D, Type 2 Diabetes; VAT, Visceral Adipose Tissue; WT, Wild Type. Data are presented as mean ± SEM.NAFLD vs. healthy, NAFLD vs. healthy, NAFLD vs. cirrhosis, Cirrhosis vs. healthy, Cirrhosis vs healthy, Cirrhosis vs. healthy, The mean age of patients was 50 ± 5 years in the NAFLD and 62 ± 3 years in the cirrhosis group. The mean BMI was 35 ± 2 kg/m